Researchers at The Hospital for Sick Children (SickKids) in Toronto have developed a machine-learning approach that could help resolve some of that uncertainty. The method converts blood-based epigenetic patterns into “tissue-agnostic” episignatures—molecular signals that can identify a genetic condition regardless of whether the DNA came from blood, amniotic fluid, placental tissue or another biological source. The advance could eventually make epigenetic testing more useful in prenatal medicine, where access to fetal tissues is limited and clinical decisions often must be made before birth.

The work focuses on epigenetics, the system of chemical modifications that regulates how genes operate without changing the underlying DNA sequence. One of the most important epigenetic mechanisms is DNA methylation, in which chemical groups attach to specific DNA bases and influence whether nearby genes are active or silent. Certain genetic disorders produce distinctive, disease-associated methylation patterns across the genome. These patterns, called episignatures, can act like molecular fingerprints, helping clinicians determine whether a genetic variant is likely to disrupt normal development.

The SickKids team, led by Clinical Geneticist and Senior Associate Scientist Rosanna Weksberg and Senior Research Associate Sanaa Choufani, has helped establish more than 60 episignatures. Many have already been clinically validated for diagnostic use. Traditionally, however, these signatures have been considered tissue-specific. A methylation pattern identified in blood might not be directly applicable to DNA extracted from prenatal samples, because different tissues undergo distinct developmental and regulatory processes. That limitation has prevented many families undergoing prenatal testing from benefiting from episignature-based analysis.

To test whether this barrier could be overcome, the researchers first generated a blood-derived episignature for Down syndrome, a condition caused in most cases by an extra copy of chromosome 21. The signature was built using samples from 266 people with Down syndrome. The team then used publicly available DNA methylation data from 850 individuals with and without the condition to train a machine-learning model. The dataset included six prenatal and postnatal tissue types, allowing the researchers to compare disease-associated methylation patterns across tissues with very different biological functions.

Rather than searching for a single methylation site, the model analyzed coordinated changes across numerous regions of the genome. Machine-learning algorithms can identify combinations of features that are difficult to recognize through manual inspection, including patterns that remain biologically meaningful even when their strength varies between tissues. In this case, the model was designed to preserve the core information of the blood-derived Down syndrome signature while adapting it to the molecular characteristics of other tissues.

The results demonstrated that the transformed signature accurately recognized the Down syndrome pattern in every tissue type tested. This finding suggests that a blood-derived episignature can be computationally converted into a broader diagnostic signal without losing its ability to distinguish affected and unaffected samples. The result does not mean that every genetic condition will produce a universal signature, but it provides proof that tissue-specificity—one of the major challenges in epigenetic diagnostics—may be reduced with carefully trained models and sufficiently diverse reference data.

The potential clinical impact is particularly important for prenatal diagnosis. Amniotic fluid and placental tissue may be available during pregnancy, but they are not equivalent to blood and can contain limited amounts of DNA. A tissue-agnostic episignature could allow clinicians to compare prenatal methylation data with established diagnostic patterns even when the original signature was discovered in postnatal blood. In practical terms, the approach could help interpret uncertain variants and provide families with more precise information at a time when uncertainty can have profound emotional and medical consequences.

The researchers also believe the strategy could eventually expand testing beyond conventional blood samples. Saliva and oral swabs, which are easier and less invasive to collect, may become useful sources of DNA if their molecular signals can be reliably connected to disease-associated episignatures. Such applications would require extensive validation across larger and more diverse populations, as well as careful assessment of false-positive and false-negative results. Machine-learning systems must also be tested in real clinical settings to ensure that their predictions remain reliable when samples vary in quality, ancestry, developmental stage and medical history.

The study, published in The American Journal of Human Genetics, represents an early but significant step toward more flexible epigenetic diagnostics. By combining genome-scale methylation analysis with machine learning, the SickKids team has shown that information discovered in one tissue can potentially be translated to others. The researchers say the long-term goal is to shorten the diagnostic odyssey experienced by many children and families affected by rare genetic disorders, while giving clinicians clearer evidence for interpreting uncertain variants. Supported by the Canadian Institutes of Health Research, the work could help advance a more individualized approach to prenatal and pediatric care, in which molecular data are used not only to diagnose disease but also to guide families through some of medicine’s most difficult decisions.

Subject of Research: Tissue-agnostic epigenetic signatures and machine-learning-assisted interpretation of genetic variants for prenatal diagnosis.

Web References: The American Journal of Human Genetics study; EpigenCentral; Rosanna Weksberg; SickKids Genetics & Genome Biology.

References: American Journal of Human Genetics; The Hospital for Sick Children; Canadian Institutes of Health Research.

Image Credits: The Hospital for Sick Children.

Keywords

Prenatal genetic testing, variants of uncertain significance, episignatures, DNA methylation, epigenetics, tissue-agnostic diagnostics, machine learning, Down syndrome, prenatal medicine, genetic disorders, medical genetics, SickKids

Despite advances in understanding autism’s neurodevelopmental origins, early detection remains a formidable challenge. Autism-related brain changes typically commence prenatally, yet behavioral manifestations often emerge gradually, eluding timely clinical identification. Dr. Rujuta Wilson, the pediatric neurologist leading the project at UCLA Health, emphasizes that early detection and intervention are paramount for maximizing developmental potential in affected individuals. However, traditional evaluations primarily focus on gross motor milestones such as crawling or sitting, often overlooking more nuanced irregularities in movement that precede overt symptoms.

The cornerstone of this research is the deployment of wearable sensors resembling miniature fitness trackers, designed to passively and continuously monitor infant motor activity in naturalistic home environments. These sensors, affixed comfortably to infants’ wrists and ankles within soft arm and leg warmers, will capture rich datasets encompassing movement frequency, variability, and coordination from three to twelve months of age. The design ensures minimal disruption to infants and families while generating high-resolution data rarely accessible through conventional clinical observation.

The choice to study infants at elevated risk—those with an older sibling diagnosed with autism spectrum disorder—is a deliberate strategy to enrich the sample with participants more likely to develop similar conditions, thereby optimizing the predictive power of the metrics derived from movement analysis. Behavioral and developmental assessments will complement sensor data at three-month intervals, with rigorous diagnostic evaluations scheduled at one and two years of age to identify emerging signs of autism or other developmental delays.

Historically, motor impairments in autistic children have been underappreciated and undertreated, partly due to their subtlety and the challenge of quantification in clinical settings. These early motor difficulties—manifesting as impaired coordination or abnormalities in grasping objects—often contribute to cascading developmental challenges. Impaired motor skills can impede environmental exploration, social engagement, and language acquisition, setting back a child’s trajectory across multiple domains. Addressing these challenges early could mitigate long-term functional impairments.

This study builds upon promising preliminary findings from Dr. Wilson’s laboratory, which have demonstrated that specific metrics of infant movement variability serve as robust predictors of later autism diagnosis. By harnessing sophisticated machine learning algorithms, the research team aims to refine these movement biomarkers into a comprehensive battery capable of reliably forecasting developmental risk. Such analytic models could ultimately be integrated into routine pediatric well-child visits to enable scalable, low-cost early screening.

Moreover, the project prioritizes accessibility, with most assessments conducted in the infant’s home environment. This reduces barriers for families and allows for data collection within a naturalistic context, providing more ecologically valid insights into infant motor patterns. Families will receive timely verbal and written reports on their child’s developmental status and can consult directly with the clinicians, fostering an informative feedback loop critical for early engagement.

The implications of this work extend beyond autism alone. Enhanced early detection of motor irregularities could flag a spectrum of developmental conditions, facilitating earlier referrals to targeted therapies designed to bolster functional abilities and independence. Such a paradigm shift in early neurodevelopmental surveillance holds potential to transform clinical practice, shifting the focus from reactive diagnosis to proactive monitoring.

Incorporating wearable sensor technology and data science within pediatric neurology introduces a potent toolset to uncover subtle, previously inaccessible motor signatures. This confluence of technology and developmental science epitomizes precision medicine’s promise to tailor surveillance and intervention strategies according to individual risk profiles. The UCLA team’s longitudinal design ensures capturing developmental trajectories over a crucial period, enriching understanding of how early motor patterns evolve in typical versus atypical development.

Timely identification of autism spectrum disorder remains one of modern neurodevelopmental medicine’s greatest hurdles, with current diagnostic practices typically detecting autism around two or three years of age, well after critical intervention windows. The UCLA-led endeavor seeks to close this gap, implementing innovative sensor-based methodologies that detect early motor perturbations, setting the stage for intervention during the plastic and highly responsive neural periods of infancy.

Set to conclude in December 2030, this five-year research initiative represents a significant commitment to advancing developmental neuroscience and clinical care. By integrating cutting-edge wearable technologies, rigorous behavioral assessment, and machine learning, the investigators aim to establish scalable predictors that will be vital for pediatricians, neurologists, and families alike in the early recognition and treatment of autism and related conditions.

The support granted by the National Institute of Neurologic Disorders and Stroke (grant number 1R01NS142720-01A1) underscores the strategic importance of this work within national research priorities. As this study unfolds, it promises to enrich scientific understanding, offer novel clinical tools, and potentially revolutionize early developmental screening paradigms nationwide.

Subject of Research: Early identification of autism and developmental disorders through wearable sensor technology monitoring infant motor activity.

Article Title: UCLA Health Researchers Harness Wearable Technology for Early Autism Detection

News Publication Date: January 2024

Web References:

• UCLA Health Provider – Dr. Rujuta Wilson
• Prior Research on Movement Variability and Autism
• Study on Child Neurologists’ Role in Autism
• Earlier Research Metrics with Predictive Value

References:
National Institute of Neurologic Disorders and Stroke Grant 1R01NS142720-01A1

Keywords

Autism, Neurodevelopment, Wearable Technology, Motor Development, Infant Monitoring, Early Detection, Developmental Disorders, Machine Learning, Pediatric Neurology, Movement Variability, Early Intervention